Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Brain Neoplasms 206Glioblastoma 169Central Nervous System Neoplasms 138Astrocytoma 135Gliosarcoma 132Neuroblastoma 109Glioma 104Oligodendroglioma 87Medulloblastoma 68Sarcoma 51Neoplasms 45Ependymoma 43Osteosarcoma 40Wilms Tumor 39Familial ependymoma 38Neuroectodermal Tumors, Primitive, Peripheral 36Optic Nerve Glioma 33Breast Neoplasms 33Lymphoma, Non-Hodgkin 32Neurofibromatosis 1 31Choroid Plexus Neoplasms 29Lymphoma 28Burkitt Lymphoma 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Rhabdomyosarcoma 23Rhabdoid Tumor 23Recurrence 21Meningioma 21Carcinoma, Non-Small-Cell Lung 21Testicular Neoplasms 20

Interventions

enasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sinonasal undifferentiated carcinoma × CNS × Clear all
NCT06176989 2026-06-03

Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
40 enrolled
CNSSarcoma

Sinonasal undifferentiated carcinoma, Chondrosarcoma, Esthesioneuroblastoma, Olfactory

Data powered by HemOnc (CC BY 4.0) Colophon âš¡